文献速递头颈外科

帕博利珠单抗联合四联放疗治疗复发/不可切除或转移性头颈癌的非随机临床试验

Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-01-01

这项单臂2期非随机临床试验在单个学术性综合癌症中心开展,纳入21例拟接受帕博利珠单抗单药治疗且头颈部有适合四联放疗靶点的复发、不可切除或转移性头颈鳞癌患者。15例可评估患者的总体缓解率为47%(95%CI 21%-73%),20例治疗患者的中位无进展生存期9.2个月、中位总生存期14.9个月。3级和4级不良事件分别发生于6例和2例患者。

要点

  • 帕博利珠单抗联合四联放疗在复发/不可切除或转移性头颈鳞癌中可行,总体缓解率47%。
  • 可评估患者中位无进展生存期11.5个月,中位总生存期15.3个月。
  • 3级和4级不良事件分别见于6例和2例患者,患者报告不良事件随时间无实质变化。

核心结论

  • 帕博利珠单抗联合四联放疗在复发、不可切除或转移性头颈鳞癌中可行,并显示潜在获益的初步证据,值得未来随机临床试验进一步研究。

研究设计与样本

  • 单臂2期非随机临床试验,在单个美国国家癌症研究所指定的综合癌症中心开展,2021年2月至2024年5月入组并治疗。
  • 筛查29例,入组21例,其中15例符合主要终点缓解分析条件;治疗患者20例。
  • 干预为帕博利珠单抗200 mg/m2每3周一次直至疾病进展、不耐受或最长2年,联合四联放疗14.8 Gy分4次每次3.7 Gy、连续两日每日两次,在帕博利珠单抗周期之间循环给予。

主要发现

  • 可评估患者总体缓解率为47%(95%CI 21%-73%)。
  • 20例治疗患者中位无进展生存期9.2个月(95%CI 3-17),中位总生存期14.9个月(95%CI 5至不可估计)。
  • 15例主要终点可评估患者中位无进展生存期11.5个月(95%CI 5.1至不可估计),中位总生存期15.3个月(95%CI 6.3至不可估计)。
  • 3级和4级不良事件分别发生于6例和2例患者,患者报告不良事件随时间无实质变化。

关键数值与推荐

  • 主要终点为至少一次缓解评估患者的总体缓解率,采用实体瘤疗效评价标准1.1版。
  • 次要终点包括无进展生存期、总生存期、临床医生评定(常见不良事件评价标准5.0版)和患者报告(患者报告结局版常见不良事件评价标准1.0版)的不良事件。

临床怎么用

  • 对于拟接受帕博利珠单抗单药治疗且头颈部存在适合四联放疗靶点的复发、不可切除或转移性头颈鳞癌患者,可考虑帕博利珠单抗联合四联放疗。
  • 治疗期间需监测3级和4级不良事件,并关注患者报告的不良事件变化。

局限性

  • 单臂、非随机设计,样本量小,主要终点可评估患者仅15例。
  • 在单个学术性综合癌症中心开展,结果外推需谨慎。
  • 为2期初步证据,尚需随机临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitor (ICI) monotherapy for patients with recurrent, unresectable, or metastatic (RUM) head and neck squamous cell carcinoma (HNSCC) is associated with poor outcomes. Low-dose, hypofractionated, quad-shot radiotherapy (QSRT) may enhance the efficacy of ICIs. OBJECTIVE: To evaluate the efficacy and toxic effects of ICIs in combination with QSRT for patients with RUM HNSCC that is amenable to QSRT. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, phase 2, nonrandomized clinical trial was conducted at a single, academic, National Cancer Institute-designated Comprehensive Cancer Center and included patients with RUM HNSCC who were going to receive treatment with pembrolizumab monotherapy and had a targetable site in the head and neck that was amenable to QSRT (based on location, prior radiotherapy dose, and tolerance). Patients were enrolled and treated between February 2021 and May 2024. INTERVENTIONS: Pembrolizumab (200 mg/m2) was administered every 3 weeks until disease progression, intolerance, or a maximum duration of 2 years. QSRT comprised 14.8 Gy in four 3.7-Gy fractions that were delivered twice daily on consecutive days. QSRT courses were delivered cyclically between pembrolizumab cycles. MAIN OUTCOMES AND MEASURES: The primary outcome was overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, in patients with at least 1 response assessment. Secondary outcomes were progression-free survival (PFS), overall survival (OS), and clinician-rated (Common Terminology Criteria for Adverse Events, version 5.0) and patient-reported (patient-reported outcomes version of the Common Terminology Criteria for Adverse Events, version 1.0) adverse effects (AEs). RESULTS: Of the 29 individuals who were screened, 21 enrolled, and 15 patients (median [range] age, 61 [33-86] years) were eligible for response analysis: 5 women (33.3%), 10 men (66.7%), 9 individuals with oropharyngeal/oral cavity primary tumors, and 14 current/former smokers (93.3%). Fourteen patients had received prior systemic therapy, and 11 had received prior RT. Among evaluable patients, the overall response rate was 47% (95% CI, 21%-73%). Median PFS and OS among the treated patients (n = 20) were 9.2 months (95% CI, 3-17) and 14.9 months (95% CI, 5 to not estimable), respectively. For the 15 patients who were evaluable for the primary end point, median PFS was 11.5 months (95% CI, 5.1 to not estimable), and median OS was 15.3 months (95% CI, 6.3 to not estimable). Grade 3 and 4 AEs occurred for 6 and 2 patients, respectively. Patient-reported AEs did not substantially change over time. CONCLUSIONS AND RELEVANCE: This nonrandomized trial demonstrated the feasibility of pembrolizumab plus QSRT for patients with RUM HNSCC and provides preliminary evidence of a potential benefit to this novel combination that warrants investigation in future randomized clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04454489.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Hughes RT, Smith S, Lycan TW, et al. Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42313403. doi:10.1001/jamaoto.2026.1527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。